Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-TCRVβ2 CAR-iNKT cells
- Development stage
- Preclinical
- Lead developer
- Imperial College London
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-TCRVβ2 CAR-iNKT cells are an experimental allogeneic cell therapy consisting of invariant natural killer T (iNKT) cells engineered to express a chimeric antigen receptor (CAR) targeting the TCRVβ2 subunit of the T-cell receptor. Developed by the Karadimitris Lab at Imperial College London, this therapy is designed to treat T-cell malignancies, particularly Adult T-cell leukaemia/lymphoma (ATL) and other peripheral T-cell lymphomas (TCL) that clonally express the TCRVβ2 chain. By targeting a specific TCRVβ family, the therapy aims to eliminate malignant clones while sparing the majority of the healthy T-cell repertoire. The use of iNKT cells as effectors facilitates an "off-the-shelf" allogeneic approach because these cells do not induce graft-versus-host disease (GVHD).
- Other names
- anti-TCRVβ2 CAR-iNKTTCRVβ2 CAR-iNKT cells
02
Targets
TRBV2 (T-cell receptor beta variable 2)
Beyond the preview
Go deeper on anti-TCRVβ2 CAR-iNKT cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-TCRVβ2 CAR-iNKT cells.